Search

Your search keyword '"Krol, Augustinus D. G."' showing total 2 results
Start Over Author "Krol, Augustinus D. G." Database OpenAIRE
2 results on '"Krol, Augustinus D. G."'

1. Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma

Author

Opstal-van Winden, Annemieke W J, de Haan, Hugoline G, Hauptmann, Michael, Schmidt, Marjanka K, Broeks, Annegien, Russell, Nicola S, Janus, Cécile P M, Krol, Augustinus D G, van der Baan, Frederieke H, De Bruin, Marie L, van Eggermond, Anna M, Dennis, Joe, Anton Culver, Hoda, Haiman, Christopher A, Sawyer, Elinor J, Cox, Angela, Devilee, Peter, Hooning, Maartje J, Peto, Julian, Couch, Fergus J, Pharoah, Paul, Orr, Nick, Easton, Douglas F, Aleman, Berthe M P, Strong, Louise C, Bhatia, Smita, Cooke, Rosie, Robison, Leslie L, Swerdlow, Anthony J, van Leeuwen, Flora E, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Radiotherapy, Medical Oncology, de Haan, Hugoline G [0000-0003-1126-4776], Schmidt, Marjanka K [0000-0002-2228-429X], De Bruin, Marie L [0000-0001-9197-7068], Dennis, Joe [0000-0003-4591-1214], Pharoah, Paul [0000-0001-8494-732X], Apollo - University of Cambridge Repository, Afd Pharmacoepi & Clinical Pharmacology, and Pharmacoepidemiology and Clinical Pharmacology

Subjects
0301 basic medicine, Oncology, Neoplasms, Radiation-Induced, medicine.medical_treatment, Biochemistry, single nucleotide polymorphisms, 0302 clinical medicine, Cancer Survivors, Genotype, Taverne, Odds Ratio, Young adult, skin and connective tissue diseases, Aged, 80 and over, education.field_of_study, Neoplasms, Second Primary, Radiotherapy Dosage, Hematology, Middle Aged, Hodgkin Disease, 030220 oncology & carcinogenesis, Regression Analysis, Female, Adult, Quality Control, Risk, medicine.medical_specialty, Immunology, Population, Breast Neoplasms, Polymorphism, Single Nucleotide, 03 medical and health sciences, Young Adult, Breast cancer, breast cancer, SDG 3 - Good Health and Well-being, Internal medicine, medicine, Genetic predisposition, Humans, Genetic Predisposition to Disease, education, radiotherapy, Aged, business.industry, Case-control study, Cell Biology, Odds ratio, medicine.disease, Radiation therapy, 030104 developmental biology, Case-Control Studies, polygenic risk score, business, Hodgkin lymphoma, genetic susceptibility
Abstract

Female Hodgkin lymphoma (HL) patients treated with chest radiotherapy (RT) have a very high risk of breast cancer. The contribution of genetic factors to this risk is unclear. We therefore examined 211 155 germline single-nucleotide polymorphisms (SNPs) for gene-radiation interaction on breast cancer risk in a case-only analysis including 327 breast cancer patients after chest RT for HL and 4671 first primary breast cancer patients. Nine SNPs showed statistically significant interaction with RT on breast cancer risk (false discovery rate

Published
2019

2. Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure

Author

Krul, Inge M, Opstal-van Winden, Annemieke W J, Aleman, Berthe M P, Janus, Cécile P M, van Eggermond, Anna M, De Bruin, Marie L, Hauptmann, Michael, Krol, Augustinus D G, Schaapveld, Michael, Broeks, Annegien, Kooijman, Karen R, Fase, Sandra, Lybeert, Marnix L, Zijlstra, Josée M, van der Maazen, Richard W M, Kesminiene, Ausrele, Diallo, Ibrahima, de Vathaire, Florent, Russell, Nicola S, van Leeuwen, Flora E, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Radiotherapy, CCA - Cancer Treatment and quality of life, Hematology, APH - Quality of Care, and Epidemiology and Data Science

Subjects
Oncology, Cancer Research, Neoplasms, Radiation-Induced, Time Factors, medicine.medical_treatment, Menopause, Premature, Procarbazine, Noninfiltrating, 0302 clinical medicine, Risk Factors, Neoplasms, Taverne, 030212 general & internal medicine, Breast, Survivors, Young adult, Gonadal Steroid Hormones, Netherlands, Radiation, Radiotherapy Dosage, Middle Aged, Alkylating, Hodgkin Disease, Menopause, 030220 oncology & carcinogenesis, Female, medicine.drug, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], Adult, medicine.medical_specialty, Hormone Replacement Therapy, Intraductal, Antineoplastic Agents, Breast Neoplasms, Dose-Response Relationship, 03 medical and health sciences, Young Adult, Breast cancer, SDG 3 - Good Health and Well-being, Internal medicine, Journal Article, medicine, Confidence Intervals, Humans, Radiology, Nuclear Medicine and imaging, Premature, Antineoplastic Agents, Alkylating, Gynecology, business.industry, Carcinoma, Ovary, Case-control study, Dose-Response Relationship, Radiation, Odds ratio, medicine.disease, Radiation therapy, Carcinoma, Intraductal, Noninfiltrating, Radiation-Induced, Case-Control Studies, business, Hormone
Abstract

Item does not contain fulltext BACKGROUND: Young women treated with chest radiation therapy (RT) for Hodgkin lymphoma (HL) experience a strongly increased risk of breast cancer (BC). It is unknown whether endogenous and exogenous gonadal hormones affect RT-associated BC risk. METHODS: We conducted a nested case-control study among female 5-year HL survivors treated before age 41. Hormone exposure and HL treatment data were collected through medical records and questionnaires for 174 BC case patients and 466 control patients. Radiation dose to breast tumor location was estimated based on RT charts, simulation films, and mammography reports. RESULTS: We observed a linear radiation dose-response curve with an adjusted excess odds ratio (EOR) of 6.1%/Gy (95% confidence interval [CI]: 2.1%-15.4%). Women with menopause /=50 years. BC risk increased by 6.4% per additional year of post-RT intact ovarian function (P/=2 years did not increase BC risk (OR, 0.86; 95% CI, 0.32-2.32), whereas this risk was nonsignificantly increased among women without early menopause (OR, 3.69; 95% CI, 0.97-14.0; P for interaction: .06). Stratification by duration of post-RT intact ovarian function or HRT use did not statistically significantly modify the radiation dose-response curve. CONCLUSIONS: BC risk in female HL survivors increases linearly with radiation dose. HRT does not appear to increase BC risk for HL survivors with therapy-induced early menopause. There are no indications that endogenous and exogenous gonadal hormones affect the radiation dose-response relationship.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results